CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.31 -0.12 (-0.22%)

Delayed Quote Updated: 11:47 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

37 38 Next >

3 Dirt Cheap Stocks to Buy Right Now ↗

September 21, 2024

Bargain hunters should love these great stocks.

Via The Motley Fool

Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy? ↗

September 19, 2024

There's a lot of growth on the way, and soon.

Via The Motley Fool

1 Biotech Stock Down 62% to Buy and Hold ↗

September 12, 2024

It's an excellent opportunity to buy shares of what could become a biotech giant on the dip.

Via The Motley Fool

3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗

September 12, 2024

An investment in these players today could score a big win down the road.

Via The Motley Fool

Looking for Stock Bargains With Room to Run? Try This. ↗

September 11, 2024

Investing tips from Bill Mann, The Motley Fool's director of small-cap research.

Via The Motley Fool

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal? ↗

September 05, 2024

Is the potential upside for CRISPR Therapeutics too massive to ignore?

Via The Motley Fool

3 Monster Biotech Stocks to Buy Before 2025 ↗

September 02, 2024

These companies are nearly in the sweet spot of risk versus reward in biotech.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

August 26, 2024

The companies are chasing major innovations.

Via The Motley Fool

Got the Market Sell-Off Blues? Do These 3 Things Right Now ↗

August 11, 2024

You aren't powerless in the face of what the market throws at you.

Via The Motley Fool

Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom ↗

August 08, 2024

The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is."

Via Benzinga

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

The 3 Best Gene Editing Stocks to Buy in August 2024 ↗

August 07, 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.

Via InvestorPlace

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

August 06, 2024

Shares of the rare disease drugmaker are already up more than 40% over the past year.

Via The Motley Fool

CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗

August 05, 2024

CRSP stock results show that CRISPR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Prediction: These Could Be the Best-Performing Growth Stocks Through 2030 ↗

August 05, 2024

Great companies are found in every type of market landscape.

Via The Motley Fool

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker ↗

August 04, 2024

The biotech recently became a commercial-stage company.

Via The Motley Fool

3 Unstoppable Stocks to Buy in August ↗

August 03, 2024

It's not hard to envision how all three of these stocks can deliver exceptional growth.

Via The Motley Fool

10 Best Small and Mid-Cap Stocks to Consider Buying in August ↗

August 01, 2024

A shift in market dynamics could favor these 10 growth stocks.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

July 31, 2024

The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions.

Via The Motley Fool

The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024 ↗

July 29, 2024

The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision.

Via InvestorPlace

3 Small-Cap Stocks to Buy at a 52-Week Low ↗

July 27, 2024

The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows

Via InvestorPlace

3 Gene Editing Stocks Shaping the Future of Medicine ↗

July 22, 2024

Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions

Via InvestorPlace

3 Monster Stocks in the Making to Buy Right Now ↗

July 20, 2024

They're small now, but these stocks could grow much larger.

Via The Motley Fool

3 Gene Editing Stocks That Could Grow Your Wealth ↗

July 17, 2024

Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.

Via InvestorPlace

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition ↗

July 17, 2024

Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.

Via InvestorPlace

Blue Chips, Small Caps Extending Their Breakout ↗

July 16, 2024

The Dow Jones Industrial Average is stealing the show today, last seen up 546 points for a new record high and on track for its best single-session gain since January 2023.

Via Talk Markets

Topics Stocks

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

July 16, 2024

CRISPR Therapeutics could start reporting product revenue soon.

Via The Motley Fool

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid ↗

July 11, 2024

These two stocks could have vastly different long-term performances.

Via The Motley Fool

Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates ↗

July 11, 2024

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance.

Via Benzinga

Topics ETFs

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

July 11, 2024

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Via MarketBeat

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.